Home>Topics>Stocks>Neurocrine Biosciences

Neurocrine Biosciences NBIX

  1. All
  2. Commentary
  3. Headlines
    1. Neurocrine Biosciences' ( NBIX ) CEO Kevin Gorman Presents at Morgan Stanley Healthcare Conference (Transcript)

      Headlines

      Wed, 10 Sep 2014

      By SA Transcripts : Neurocrine Biosciences , Inc. (NASDAQ: NBIX ) Morgan Stanley Healthcare Conference Call September 10, 2014 11:30 AM ET Executives Kevin Gorman - Chief Executive Officer

    2. Neurocrine Biosciences Moving Ahead With '854

      Headlines

      Sat, 9 Aug 2014

      There were no blockbuster announcements from Neurocrine Biosciences (NASDAQ: NBIX ) this quarter, but the company now has ..... Dyskinesia The most important update from Neurocrine Biosciences concerned its plans for Phase III testing

    3. Neurocrine Biosciences' ( NBIX ) CEO Kevin Gorman on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 7 Aug 2014

      Neurocrine Biosciences , Inc. (NASDAQ: NBIX ) Q2 2014 Earnings Conference Call August 7, 2014 08 ..... Presentation Operator Good day, everyone and welcome to Neurocrine Biosciences Second Quarter Earnings Call. At this time, all participants

    4. Neurocrine Biosciences EPS in-line

      Headlines

      Wed, 6 Aug 2014

      Neurocrine Biosciences (NASDAQ: NBIX ): Q2 EPS of -$0.18 in-line. Press Release Post your comment!

    5. Notable earnings after Wednesday’s close

      Headlines

      Tue, 5 Aug 2014

      INWK , IO , ITMN , IXYS , JACK , KEG , KND , KW , LGP , LHCG , LNT , MBI , MCP , MG , MHLD , MNTX , MRIN , MTDR , MUSA , MWE , NBIX , NLY , NPSP , NRP , NVAX , NVTL , OILT , OSUR , PAA , PACD , PKT , PMT , PPO , PRI , PRU , PRXL , PTLA , QEP , RAIL , REG

    6. CLS: Slow Down, Think Before You Trade

      Headlines

      Wed, 15 Jan 2014

      On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine

    7. Dropping Coverage of Neurocrine

      Commentary

      Mon, 31 Aug 2009

      We are no longer providing equity research on Neurocrine Biosciences NBIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    8. Neurocrine Searches for Catalyst

      Commentary

      Tue, 16 Jun 2009

      Neurocrine Biosciences NBIX still lacks a compelling late-stage drug candidate. Its indiplon program is dead for now; the company is still waiting on final

    9. Neurocrine under Review

      Commentary

      Thu, 13 Dec 2007

      We're placing Neurocrine Bioscience's NBIX fair value estimate under review following the receipt of its second approvable letter for indiplon. We plan a significant reduction

    10. Neurocrine Resubmits Indiplon

      Commentary

      Wed, 1 Aug 2007

      Neurocrine Biosciences NBIX announced the resubmission of its new drug application for indiplon capsules on July 31. This does not change our fair value estimate

    « Prev12Next »
    Content Partners